Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

PF-06821497 Traitement du CPPC récidivant/réfractaire, du cancer de la prostate résistant à la castration et du lymphome folliculaire

9 novembre 2026 mis à jour par: Pfizer

UNE PHASE I D'ESCALADE DE DOSE ET UNE ÉTUDE DE COHORTE ÉLARGIE DU PF-06821497 DANS LE TRAITEMENT DE PATIENTS ADULTES ATTEINTS D'UN CANCER DU POUMON À PETITES CELLULES (SCLC) EN RECHUTE/RÉFRACTAIRE, D'UN CANCER DE LA PROSTATE RÉSISTANT À LA CASTRATION (CRPC) ET D'UN LYMPHOME FOLLICULAIRE (LF)

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.

Part 3, which is open for enrollment is seeking men who:

  • have Castration Resistant Prostate Cancer (CRPC) and
  • have previously received treatment for CRPC and have progressed from the last treatment

All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).

In the assessment phase:

  • participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
  • participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
  • participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.

After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.

The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Intervention / Traitement

Description détaillée

This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).

Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.

Type d'étude

Interventionnel

Inscription (Estimé)

453

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Haskovo, Bulgarie, 6300
        • Résilié
        • Specialized Hospital for Active Treatment of Oncology - Haskovo
    • Guangdong
      • Guangzhou, Guangdong, Chine, 510120
        • Actif, ne recrute pas
        • The First Affiliated Hospital of Guangzhou Medical University
    • Hunan
      • Changsha, Hunan, Chine, 410013
        • Actif, ne recrute pas
        • Hunan Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Chine, 210009
        • Actif, ne recrute pas
        • Zhongda Hospital Southeast University
      • Nanjing, Jiangsu, Chine, 210008
        • Actif, ne recrute pas
        • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    • Sichuan
      • Chengdu, Sichuan, Chine, 610041
        • Recrutement
        • West China Hospital, Sichuan University
    • Zhejiang
      • Wenzhou, Zhejiang, Chine, 325000
        • Actif, ne recrute pas
        • The First Affiliated Hospital of Wenzhou Medical University
    • Kyǒnggi-do
      • Seongnam, Kyǒnggi-do, Corée du Sud, 13620
        • Recrutement
        • Seoul National University Bundang Hospital
    • Seoul-teukbyeolsi [seoul]
      • Seoul, Seoul-teukbyeolsi [seoul], Corée du Sud, 03080
        • Actif, ne recrute pas
        • Seoul National University Hospital
      • Seoul, Seoul-teukbyeolsi [seoul], Corée du Sud, 07985
        • Actif, ne recrute pas
        • Ewha Womans University Mokdong Hospital
      • Seoul, Seoul-teukbyeolsi [seoul], Corée du Sud, 03722
        • Actif, ne recrute pas
        • Severance Hospital, Yonsei University Health System
    • Taejǒn-kwangyǒkshi
      • Daejeon, Taejǒn-kwangyǒkshi, Corée du Sud, 35015
        • Actif, ne recrute pas
        • Chungnam national university hospital
      • Barcelona, Espagne, 08035
        • Recrutement
        • Hospital Universitari Vall d'Hebron
      • Barcelona, Espagne, 08036
        • Recrutement
        • Hospital Clinic de Barcelona
      • Barcelona, Espagne, 08023
        • Recrutement
        • Hospital Quironsalud Barcelona
      • Madrid, Espagne, 28034
        • Recrutement
        • Hospital Universitario Ramon y Cajal
      • Madrid, Espagne, 28050
        • Recrutement
        • Hospital Universitario HM Sanchinarro
      • Madrid, Espagne, 28040
        • Recrutement
        • H.U. Fundación Jiménez Díaz
      • Madrid, Espagne, 28041
        • Recrutement
        • Hospital Universitario 12 De Octubre
      • Málaga, Espagne, 29010
        • Recrutement
        • Hospital Universitario Virgen de la Victoria
      • Valencia, Espagne, 46026
        • Actif, ne recrute pas
        • Hospital Universitari i Politecnic La Fe
    • Barecelona
      • L'Hospitalet de Llobregat, Barecelona, Espagne, 08908
        • Actif, ne recrute pas
        • Institut Català d´Oncología (ICO)-H. Durán i Reynals
    • Castellon
      • Castellon, Castellon, Espagne, 12002
        • Actif, ne recrute pas
        • Consorcio Hospitalario Provincial de Castellon
    • Madrid
      • Pozuelo de Alarcón, Madrid, Espagne, 28223
        • Recrutement
        • Hospital Quironsalud Madrid
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Espagne, 28040
        • Recrutement
        • Hospital Clinico San Carlos
    • Chiba
      • Kashiwa, Chiba, Japon, 277-8577
        • Actif, ne recrute pas
        • National Cancer Center Hospital East
      • Bydgoszcz, Pologne, 85-048
        • Pas encore de recrutement
        • In-Vivo Sp. z o.o. In-vivo Bydgoszcz
      • Koszalin, Pologne, 75-581
        • Actif, ne recrute pas
        • Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
      • Krakow, Pologne, 30-348
        • Recrutement
        • Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
      • Rzeszów, Pologne, 35-326
        • Actif, ne recrute pas
        • Centrum Medyczne MEDYK
      • Warsaw, Pologne, 02-781
        • Actif, ne recrute pas
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
      • Moscow, Russie, 117186
        • Actif, ne recrute pas
        • LLC "Neyro-klinika"
      • Moscow, Russie, 125284
        • Résilié
        • Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
      • Moscow, Russie, 129301
        • Résilié
        • SBHI of Moscow City Clinical Hospital
      • Omsk, Russie, 644013
        • Résilié
        • Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
      • Saint Petersburg, Russie, 197341
        • Résilié
        • Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
      • Saint Petersburg, Russie, 197758
        • Résilié
        • Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
      • Saint Petersburg, Russie, 198255
        • Résilié
        • Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
      • Yaroslavl, Russie, 150054
        • Résilié
        • State Budgetary Healthcare Institution of the Yaroslavl Region
    • Sankt-Peterburg
      • Pushkin, Sankt-Peterburg, Russie, 196603
        • Actif, ne recrute pas
        • Private Medical Institution "Euromedservice"
    • Arizona
      • Tucson, Arizona, États-Unis, 85719
        • Actif, ne recrute pas
        • Banner-University Medical Center Tucson
      • Tucson, Arizona, États-Unis, 85719
        • Actif, ne recrute pas
        • The University of Arizona Cancer Center-North Campus
      • Tucson, Arizona, États-Unis, 85724
        • Actif, ne recrute pas
        • The University of Arizona Cancer Center
      • Tucson, Arizona, États-Unis, 85741
        • Résilié
        • Arizona Urology Specialists, PLLC
    • California
      • Anaheim, California, États-Unis, 92801
        • Actif, ne recrute pas
        • Pacific Cancer Medical Center INC
      • Duarte, California, États-Unis, 91010
        • Actif, ne recrute pas
        • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
      • Duarte, California, États-Unis, 91010
        • Actif, ne recrute pas
        • City of Hope Investigational Drug Services (IDS)
    • Connecticut
      • Norwalk, Connecticut, États-Unis, 06856
        • Actif, ne recrute pas
        • Norwalk Hospital
    • Kansas
      • Fairway, Kansas, États-Unis, 66205
        • Actif, ne recrute pas
        • The University of Kansas Cancer Center, Investigational Drug Services
      • Fairway, Kansas, États-Unis, 66205
        • Actif, ne recrute pas
        • The University of Kansas Clinical Research Center
      • Kansas City, Kansas, États-Unis, 66160
        • Actif, ne recrute pas
        • The University of Kansas Hospital
      • Kansas City, Kansas, États-Unis, 66160
        • Actif, ne recrute pas
        • The University of Kansas Medical Center Medical Office Building
      • Overland Park, Kansas, États-Unis, 66211
        • Actif, ne recrute pas
        • The University of Kansas Cancer Center - Indian Creek Campus
      • Westwood, Kansas, États-Unis, 66205
        • Actif, ne recrute pas
        • The University of Kansas Cancer Center
    • Kentucky
      • Louisville, Kentucky, États-Unis, 40202
        • Actif, ne recrute pas
        • Norton Cancer Institute, Norton Healthcare Pavilion
      • Louisville, Kentucky, États-Unis, 40202
        • Actif, ne recrute pas
        • Norton Hospital
      • Louisville, Kentucky, États-Unis, 40202
        • Actif, ne recrute pas
        • Norton Cancer Institute - Downtown
    • Maryland
      • Rockville, Maryland, États-Unis, 20850
        • Résilié
        • Maryland Oncology Hematology, P.A.
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Actif, ne recrute pas
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, États-Unis, 02115
        • Actif, ne recrute pas
        • Brigham and Women's Hospital
      • Newton, Massachusetts, États-Unis, 02459
        • Actif, ne recrute pas
        • Dana Farber Cancer Institute- Chestnut Hill
    • Nebraska
      • Omaha, Nebraska, États-Unis, 68130
        • Recrutement
        • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    • New Jersey
      • Hackensack, New Jersey, États-Unis, 07601
        • Actif, ne recrute pas
        • Hackensack University Medical Center
      • Hackensack, New Jersey, États-Unis, 07601
        • Actif, ne recrute pas
        • John Theurer Cancer Center at Hackensack University Medical Center
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Recrutement
        • OU Health University of Oklahoma Medical Center
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Recrutement
        • Stephenson Cancer Center (chemo location)
    • South Carolina
      • Myrtle Beach, South Carolina, États-Unis, 29572
        • Recrutement
        • Carolina Urologic Research Center
      • Myrtle Beach, South Carolina, États-Unis, 29572
        • Recrutement
        • Parkway Surgery Center
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37203
        • Recrutement
        • Sarah Cannon Research Institute - Pharmacy
      • Nashville, Tennessee, États-Unis, 37203
        • Recrutement
        • SCRI Oncology Partners
    • Texas
      • Austin, Texas, États-Unis, 78705
        • Résilié
        • Texas Oncology - Austin Midtown
      • Dallas, Texas, États-Unis, 75390
        • Actif, ne recrute pas
        • UT Southwestern Medical Center
      • Dallas, Texas, États-Unis, 75390
        • Actif, ne recrute pas
        • University of Texas Southwestern Medical Center - Simmons Cancer Center
      • Dallas, Texas, États-Unis, 75390
        • Actif, ne recrute pas
        • UT Southwestern University Hospital - William P. Clements, Jr
      • Dallas, Texas, États-Unis, 75390
        • Actif, ne recrute pas
        • UT Southwestern University Hospital - Zale Lipshy
      • Irving, Texas, États-Unis, 75063
        • Résilié
        • US Oncology Investigational Product Center (IPC)
      • Irving, Texas, États-Unis, 75063
        • Résilié
        • US Oncology Investigational Products Center
      • Irving, Texas, États-Unis, 75039
        • Recrutement
        • NEXT Dallas
      • San Antonio, Texas, États-Unis, 78229
        • Recrutement
        • NEXT Oncology
    • Virginia
      • Fairfax, Virginia, États-Unis, 22031
        • Actif, ne recrute pas
        • Virginia Cancer Specialists, PC
    • Washington
      • Port Angeles, Washington, États-Unis, 98362
        • Actif, ne recrute pas
        • Olympic Medical Center
      • Poulsbo, Washington, États-Unis, 98370
        • Actif, ne recrute pas
        • Fred Hutchinson Cancer Center Alliance Peninsula
      • Seattle, Washington, États-Unis, 98195
        • Actif, ne recrute pas
        • University of Washington Medical Center
      • Seattle, Washington, États-Unis, 98109
        • Actif, ne recrute pas
        • Fred Hutchinson Cancer Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Part 1 and Part 2 (Closed for enrollment).

Part 3 Key Inclusion Criteria:

  • Histological or cytological diagnosis of castration resistant prostate cancer.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
  • Adequate bone marrow, renal, and liver function

Part 3 Key Exclusion Criteria:

  • Prior irradiation to >25% of the bone marrow.
  • QTcF interval >480 msec at screening.
  • Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
  • Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
  • Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
  • Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
  • Prior enzalutamide within the last 4 weeks
  • DDI SUBSTUDY:
  • history of CHF or evidence of ventricular dysfunction
  • fructose intolerance
  • coadministration of CYP3A4 substrates
  • Any history of prior malignancies, except for carcinoma in situ or non-melanoma skin cancer, prior non-hematologic malignancies >= 3 years before randomization with no subsequent recurrence or progression, Stage 0 or 1 non-hematologic cancer < 3 years before randomization that has a remote probability of recurrence or progression.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Dose Escalation (Part 1A)

Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels

Oral continuous

Autres noms:
  • EZH2i
Expérimental: Dose Escalation (Part 1B)

Participants with FL will receive mevrometostat at escalating dose levels

Oral continuous

Autres noms:
  • EZH2i
Expérimental: Dose Escalation (Part 1C)

Participants with mCRPC will receive mevrometostat at escalating dose levels.

Oral continuous

Autres noms:
  • EZH2i
Expérimental: Dose Escalation (Part 2A)

Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC.

Oral continuous

Autres noms:
  • EZH2i

Oral continuous

Autres noms:
  • Xtandi
Expérimental: Dose Expansion (Part 2B)

Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone.

Oral continuous

Autres noms:
  • EZH2i

Oral continuous

Autres noms:
  • Xtandi
Expérimental: Japan Cohort

Participants with CRPC will receive mevrometostat at one or two doses

Oral continuous

Autres noms:
  • EZH2i
Expérimental: China cohort

Participants will receive mevrometostat at one or two doses

Oral continuous

Autres noms:
  • EZH2i
Expérimental: Dose Expansion (Part 2C)

Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC

Oral continuous

Autres noms:
  • EZH2i

Oral continuous

Autres noms:
  • Xtandi
Expérimental: BE Substudy

In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day.

Oral continuous

Autres noms:
  • EZH2i

Oral continuous

Autres noms:
  • Xtandi
Expérimental: DDI Substudy

The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day.

Oral continuous

Autres noms:
  • EZH2i

Oral continuous

Autres noms:
  • Xtandi

Oral solution

Autres noms:
  • Sporanox
  • Tolsura
  • Onmel

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Délai: Baseline up to 90 days

First cycle DLTs will be utilized to determine the MTD

Baseline up to 90 days
Overall safety profile including adverse events
Délai: Baseline up to approximately 2 years

Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03])

Baseline up to approximately 2 years
Preliminary efficacy determination as evaluated by disease specific response criteria
Délai: Through study completion, approximately 2 years past last patient first visit.

Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC.

Through study completion, approximately 2 years past last patient first visit.
Overall safety profile including laboratory abnormalities
Délai: Baseline up to approximately 2 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing.

Baseline up to approximately 2 years
Overall safety profile including vital signs
Délai: Baseline up to approximately 2 years

Vital sign changes from baseline including blood pressure, heart rate, ECG changes.

Baseline up to approximately 2 years
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Délai: Baseline until disease progression or death or through study completion (approx 2 years)

PCWG3

Baseline until disease progression or death or through study completion (approx 2 years)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Délai: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.

Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC)

Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
Evaluate overall survival
Délai: Baseline up to approximately 2 years

Median time to death proportion of patients alive at 6 months, 1 year, and 2 years.

Baseline up to approximately 2 years
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Single dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Délai: At specific timepoints from Cycle 1 day 1 to End of Treatment visit

Singe dose and multiple dose PK will be calculated as data permits

At specific timepoints from Cycle 1 day 1 to End of Treatment visit
Evaluate the impact of mevrometostat on patient reported outcomes.
Délai: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.

Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P.

At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Délai: At specific time points from Cycle1 Day 1 to end of treatment

Questionnaire customized from PRO-CTCAE.

At specific time points from Cycle1 Day 1 to end of treatment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Directeur d'études: Pfizer CT.gov Call Center, Pfizer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

17 avril 2018

Achèvement primaire (Estimé)

20 avril 2028

Achèvement de l'étude (Estimé)

7 juillet 2029

Dates d'inscription aux études

Première soumission

12 février 2018

Première soumission répondant aux critères de contrôle qualité

2 mars 2018

Première publication (Réel)

9 mars 2018

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

9 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • C2321001
  • 2023-509179-18-00 (Identificateur de registre: CTIS (EU))
  • EZH2 (Autre identifiant: Alias Study Number)
  • 2023 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .